Cost-analysis of a 6-week cycle of therapy with celecoxib vs conventional NSAIDs in ostheoarthritis in Italy;Analisi di costo della terapia con celecoxib vs FANS tradizionali nell'artrosi in Italia

PharmacoEconomics - Italian Research Articles

Volumn 5, Issue 1, 2003, Pages 23-34

  Lucioni, C ^a   Chiroli, S ^b   Roggeri, D ^b   Annoni, G ^c  

^a Adis International Ltd   (Italy)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; KETOPROFEN; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ALGORITHM; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEALTH CARE COST; HOSPITALIZATION; HUMAN; ITALY; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; OSTEOARTHRITIS; OUTCOMES RESEARCH; PRESCRIPTION; PROBABILITY; SENSITIVITY ANALYSIS; STOMACH ULCER;

EID: 0037237515     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320601     Document Type: Article

References (88)

1. Ciocci A. Le malattie reumatiche: aspetto statistico della malattia. Bollettino di Informazioni Medico-Statistiche 1984; 4: 14-21
2. Borda IT. The spectrum of adverse gastrointestinal effects associated with nonsteroidal anti-inflammatory drugs. In: Borda IT, Koff RS, eds. NSAIDs: a profile of adverse effects. Philadelphia: Mosby-Year Book, 1992: pp 25-80
3. Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Inter Med 1991; 115:787-96
4. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989; 96: 647-55
5. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAIDs use. Pain 2000; 85: 169-82
6. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 105: 3S-9S
7. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-35
8. Langman MJ. Epidemiology of non-steroidal anti-inflammatory drug damage to stomach and duodenum. Ital J Gastroenterol Hepatol 1999; 31: S2-S5
9. Hernandez-Diaz S, Garcia Rodriguez L. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med 2000; 160: 2093-9
10. Nobili A, Mosconi P, Franzosi MG, Tognoni G. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, a post-marketing surveillance case-control study. Pharmacoepidemiol Drug Safety 1992; 1: 65-72
11. Savage RL, Moller PV, Ballantyne CL, Wells JE. Variation in the risk of peptic ulcer complications with nonsteroidal antinflammatory drug therapy. Arthritis Rheum 1993; 36: 84-90
12. Lanza LL, Walker AM, Boetnichack EA, Dreyer NA. Peptic ulcer and gastrointestinal hemorrage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years: a large health maintenance organization cohort study. Arch Intern Med 1995; 155: 1371-7
13. Hallas J, Lauritsen J, Dalsgard Villadsen H, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk group by excess risk estimates. Scand J Gastroenterol 1995; 30: 438-44
14. Perez-Gutthann S, Garcia-Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18-24
15. Bidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: consequences and costs. Best Pract Res Clin Gastroenterol 2001; 15 (5): 739-53
16. Mc Donald TM, Morant SV, Robinson GC, et al, Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-7
17. Aalykke C, Lauritsen K. Epidemiology of NSAIDs-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001; 15: 705-22
18. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105(1B): 31S-8S
19. Langman MJ, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
20. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991; 114: 257-63
21. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from non-aspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-88
22. Beard K, Walker AM, Perera DR, Jick H. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Int Med 1987; 147: 1621-3
23. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (4): 241-9
24. Sheen CL, MacDonald TM. Gastrointestinal side effects of NSAIDs - pharmacoeconomic implications. Expert Opin Pharmacother 2002; 3 (3): 265-9
25. Moore N, Verschuren X, Montout C, et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Therapie 2000; 55 (1): 133-6
26. Rahme E, Joseph L, Kong SX, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43 (4): 917-24
27. de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol 1992; 96 (suppl): 49-53
28. Knill-Jones RP. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville. Scand J Rheumatol 1992; 96 (suppl): 59-62
29. Jonsson B, Haglund U. Economic burden of NSAID-induced gastropathy in Sweden. Scand J Gastroenterol 2001; 36 (7): 775-9
30. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001; 19 (6): 655-65
31. Sturkenboom MC, Romano F, Simon G, et al. The iatrogenic costs of NSAID therapy: A population study. Arthritis Rheum 2002; 47 (2): 132-40
32. Scarpato S, Acampora R, Corsaro S, et al. La gastroprotezione da farmaci antinfiammatori non steroidei e steroidi nelle divisioni di medicina interna: indagine sugh orientamenti prescrittivi dei medici internisti ospedalieri (Progetto Gardenia). Ann Ital Med Int 2002; 17: 41-6
33. Chevat C, Peña BM, Al MJ, Rutten FF. Healthcare resource utilization and cost of treating NSAID-associated gastrointestinal toxicity. Pharmacoeconomics 2001; 19 (Suppl 1): 17-32
34. Blower AL, Brooks A, Fenn GC, et al. Emergency admission for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11 (2): 283-91
35. Wolfe F, Kleinheksel SM, Spitz PW et al. A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges. Arthritis Rheum 1986; 29: 614-9
36. Kolodny AL, Klipper A. Final report on the cost of treating arthritic disease: comparison between salicylates and nonsalicylate nonsteroidal anti-inflammatory drugs. Seminar in Arthritis & Rheumatism 1985; 14 (Suppl 1): 20-4
37. Bloom BS. Cost of treating arthritis and NSAIDs related gastrointestinal side effects. Aliment Pharmacol Ther 1988; 2 (Suppl 1): 131-8
38. Walan A, Wahlquist P. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol 1993; 31 (Suppl 1): S79-S88
39. McDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology 2000; 39 (Suppl 2): 13-20
40. Zhao SZ, Arguelles LM, Dedhiya SD, Morgan DG. Healthcare utilization associated with dyspepsia in patients with arthritis. Am J Manag Care 1999; 5 (10): 1285-95
41. Malfertheiner P, Stanghellini V, Galmiche JP, Jones RH. Review article: managing the dyspeptic patient-an interactive discussion Aliment Pharmacol Ther 2001; 15 (Suppl 2): 14-9
42. Delaney BC, Innes MA, Decks J, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2001; (3): CD001961
43. Pillans PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust 2000; 172 (1): 16-8
44. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49 (443): 451-3
45. Chiroli S, Roggeri D. Consumo, di risorse e costi per la diagnosi e la cura degli eventi avversi gastrointestinali dovuti all'uso dei FANS. Pharmacoeconomics-Italian Research Articles 2001; 2: 61-70
46. Leardini G, Mascia MT, Stisi S, et al. Il consumo di risorse sanitarie per la cura dell'artrosi. Reumatismo 2001; 53 (3): 316-22
47. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59 (4): 957-80
48. McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30 (1): 11-8
49. Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 1999; 21 (9): 1497-513; discussion 1427-8
50. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74 (11): 1095-105
51. Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001; 29(6): 467-79
52. Tive L. Celecoxib clinical profile. Rheumatology (Oxford) 2000; 39 (Suppl 2): 21-8; discussion 57-9
53. Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19 (11): 1269-78
54. Lisse J, Espinoza L, Zhao SZ, et al. Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. J Gerontol A Biol Sci Med Sci 2001; 56 (3): M167-75
55. Bensen WG. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience. J Rheumatol Suppl 2000; 60: 17-24.
56. Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 1876-83
57. McKenna F, Arguelles L, Burke T, et al. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 2002; 20: 35-43
58. Goldstein JL, Correa P, Zhao WW et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96 (4): 1019-27
59. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354 (9196): 2106-11
60. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282 (20): 1921-8
61. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41 (9): 1591-602
62. Ashcroft DM, Chapman SR, Clark WK, Millson DS. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. Ann Pharmacother 2001; 35 (7-8): 829-34
63. Burke TA, Zabinski RA, Pettitt D, et al. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001; 19 (Suppl 1): 33-47
64. Wolfe F, Anderson J, Burke TA, et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29 (3): 467-73
65. Goldstein JL. Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib. J Rheumatol Suppl. 2000; 60: 25-8
66. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95 (7): 1681-90
67. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 284 (10): 1247-55
68. Goldstein JL. Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I Trial. Gastroenterology 2001; 120 (Suppl 1):A105
69. Simon LS, Zhao SZ, Arguelles LM, et al. Economic and gastrointestinal safety comparison of etodolac, nabumetone and oxaprozin from insurance claims data from patients with arthritis. Clin Ther 1998; 20: 1218-35
70. Hogan DB, Campbell NR, Critcher R, et al. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Assoc J 1994; 151: 315-22
71. Caruso I, Bianchi Porro G. Gastroscopic evaluation of antiinflammatory agents. BMJ 1980; 280: 75-78
72. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72
73. Lanza FL, Royer GL, Nelson RS, et al. A comparative endoscopic evaluation of damaging effects of nonsteroidal antiinflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 1981; 75: 17-21
74. Carson JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987; 147: 1054-9
75. Fries JF, Spitz PW, Williams CA, et al. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990; 33: 121-30
76. Singh G, Ramley DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther 1994; 62: 1750-91
77. Pettitt D, Goldstein JL, McGuire A, et al. Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. Rheumatology (Oxford). 2000; 39 (Suppl 2): 33-42; discussion 57-9
78. Chancellor JV, Hunsche E, de Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001; 19 (Suppl 1): 59-75
79. Zabinski RA, Burke TA, Johnson J, et al. AD economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001; 19 (Suppl 1): 49-58
80. Haglund U, Svarvar P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 (Suppl 2): 51-6
81. Svarvar P, Aly A. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology (Oxford) 2000; 39 (Suppl 2): 43-50
82. Hrachovec JB, Mora M. Reporting of 6-months vs 12-months data in a clinical trial of celecoxib. JAMA 2001; 286: 2398
83. Silverstein F, Simon L, Faich G. Reply to "Reporting of 6-months vs 12-months data in a clinical trial of celecoxib". JAMA 2001; 286: 2399
84. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal antiinflammatory drugs? BMJ 2002; 324: 1287-8
85. Geis GS. Reply to "Are selective COX-2 inhibitors superior to traditional non-steroidal antiinflammatory drugs?". BMJ 2002; 325: 161-2
86. Goldstein JL for the CLASS investigators. Gastrointestinal (GI) event rates in the CLASS study: six-months vs longer term follow-up analysis. Gastroenterology 2002; 122 (Suppl 1): A469
87. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for the treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: 619-27
88. Lu HL. Statistical reviewer briefing document for the advisory committee. www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1§ats.doc (accessibile al 3 giugno 2002)